Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.

Gardner GJ, Baser RE, Brady MF, Bristow RE, Markman M, Spriggs D, Thaler HT.

Gynecol Oncol. 2012 Feb;124(2):216-20. doi: 10.1016/j.ygyno.2011.10.021. Epub 2011 Oct 25.

PMID:
22033034
2.

CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.

Richardson DL, Seamon LG, Carlson MJ, O'Malley DM, Fowler JM, Copeland LJ, Cohn DE.

Gynecol Oncol. 2008 Nov;111(2):233-6. doi: 10.1016/j.ygyno.2008.07.035. Epub 2008 Sep 2.

PMID:
18768214
3.

Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.

Richard SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards RP, Zorn KK, Krivak TC.

Int J Gynecol Cancer. 2010 Aug;20(6):932-5. doi: 10.1111/IGC.0b013e3181e37a54.

PMID:
20683398
4.
5.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
6.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
7.

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.

Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.

Gynecol Oncol. 2010 Mar;116(3):340-4. doi: 10.1016/j.ygyno.2009.10.054. Epub 2009 Nov 17.

PMID:
19922987
8.

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, Long Roche K, Sonoda Y, Chi DS, O'Cearbhaill RE.

Gynecol Oncol. 2016 Jul;142(1):13-18. doi: 10.1016/j.ygyno.2016.05.015. Epub 2016 May 21.

9.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Apr;125(1):54-8. doi: 10.1016/j.ygyno.2011.12.417. Epub 2011 Dec 11.

10.

Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.

Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group.

J Clin Oncol. 2007 Feb 1;25(4):437-43.

PMID:
17264340
12.

Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.

Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.

Gynecol Oncol. 2000 Oct;79(1):28-32.

PMID:
11006026
13.

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD.

Gynecol Oncol. 2007 Sep;106(3):476-81. Epub 2007 Aug 3.

PMID:
17688927
14.

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM.

Gynecol Oncol. 2011 Nov;123(2):182-6. doi: 10.1016/j.ygyno.2011.07.016. Epub 2011 Aug 5.

15.

A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.

Bouchard-Fortier G, Rosen B, Vyarvelska I, Pasetka M, Covens A, Gien LT, Kupets R, Pulman K, Ferguson SE, Vicus D.

Gynecol Oncol. 2016 Jan;140(1):36-41. doi: 10.1016/j.ygyno.2015.11.005. Epub 2015 Nov 4.

PMID:
26546964
16.

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingam S; Gynecologic Oncology Group.

J Clin Oncol. 2008 Sep 1;26(25):4144-50. doi: 10.1200/JCO.2007.13.1961.

17.

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS.

J Clin Oncol. 2003 Apr 1;21(7):1313-9.

PMID:
12663720
18.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
19.

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group.

N Engl J Med. 2006 Jan 5;354(1):34-43.

20.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

Supplemental Content

Support Center